相关实验视频

Updated: Jul 18, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

网络药理学分析和实验研究的库库比他素B在口腔状细胞癌的实验研究

Zhenyuan Yu¹, Shuang Liang¹, Lanting Ji¹

¹Shanxi Province Key Laboratory of Oral Diseases Prevention and New Materials, Shanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, Shanxi, China.

Molecular diversity

|August 24, 2023

概括

库库比他B (CuB) 显示出对口腔状细胞癌 (OSCC) 的潜在作用. 网络药理学和实验表明,CuB通过向关键蛋白质和PI3K-AKT通路来抑制OSCC的生长.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

口腔状细胞癌 (OSCC) 因其高发病率和不良预后而构成重大临床挑战.
库库比他B (CuB) 是一种天然化合物,具有强大的抗癌特性,但其在OSCC中的特定机制尚未完全理解.

研究的目的:

阐明口腔状细胞癌 (OSCC) 中库库比他B (CuB) 的治疗作用和潜在机制.
在OSCC中研究CuB影响的分子标和途径,采用多方面的方法.

主要方法:

网络药理学被用来确定CuB和OSCC之间的共同目标,然后进行分子对接以验证结合.
在体外研究中评估了CuB对OSCC细胞增殖,迁移,细胞循环和细胞亡的影响.
在体内实验中,在4NQO诱导的口腔癌小鼠模型中评估了CuB的疗效.

主要成果:

网络药理学确定了134个共同目标,其中PIK3R1,SRC,STAT3,AKT1和MAPK1被强调为关键.
CuB显著抑制OSCC细胞的增殖和迁移,诱导G2阶段的停止和亡,并调节PI3K-AKT通路.
在体内,CuB有效抑制了4NQO诱导的口腔癌的发展.

结论:

通过调节多个分子标和通路,特别是PI3K-AKT信号通路,CuB表现出显著的抗OSCC活性.
这些发现支持CuB作为口腔状细胞癌的潜在治疗剂,需要进一步调查.

关键词:

库库尔比他素B的使用方法分子对接是分子对接.网络药理学网络药理学口腔状细胞癌的癌症.通过PI3K-AKT途径.

更多相关视频

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...